Top

Published in:

Open Access 01-10-2020

The Dutch LATER physical outcomes set for self-reported data in survivors of childhood cancer

Authors: Nina Streefkerk, Wim J. E. Tissing, Margriet van der Heiden-van der Loo, Elizabeth A. M. (Lieke) Feijen, Eline van Dulmen-den Broeder, Jacqueline J. Loonen, Helena J. H. van der Pal, Cécile M. Ronckers, Hanneke M. van Santen, Marleen H. van den Berg, Renée L. Mulder, Joke C. Korevaar, Leontine C. M. Kremer

Published in: Journal of Cancer Survivorship | Issue 5/2020

Abstract

Purposes

Studies investigating self-reported long-term morbidity in childhood cancer survivors (CCS) are using heterogeneous outcome definitions, which compromises comparability and include (un)treated asymptomatic and symptomatic outcomes. We generated a Dutch LATER core set of clinically relevant physical outcomes, based on self-reported data. Clinically relevant outcomes were defined as outcomes associated with clinical symptoms or requiring medical treatment.

Methods

First, we generated a draft outcome set based on existing questionnaires embedded in the Childhood Cancer Survivor Study, British Childhood Cancer Survivor Study, and Dutch LATER study. We added specific outcomes reported by survivors in the Dutch LATER questionnaire. Second, we selected a list of clinical relevant outcomes by agreement among a Dutch LATER experts team. Third, we compared the proposed clinically relevant outcomes to the severity grading of the Common Terminology Criteria for Adverse Events (CTCAE).

Results

A core set of 74 self-reported long-term clinically relevant physical morbidity outcomes was established. Comparison to the CTCAE showed that 36% of these clinically relevant outcomes were missing in the CTCAE.

Implications for Cancer Survivors

This proposed core outcome set of clinical relevant outcomes for self-reported data will be used to investigate the self-reported morbidity in the Dutch LATER study. Furthermore, this Dutch LATER outcome set can be used as a starting point for international harmonization for long-term outcomes in survivors of childhood cancer.

Available only for authorised users

Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer. 2006;42(13):2183–90. https://doi.org/10.1016/j.ejca.2006.06.006.CrossRefPubMed

Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. Lancet Oncol. 2014;15(1):35–47. https://doi.org/10.1016/S1470-2045(13)70548-5.CrossRefPubMed

Oeffinger KC, van Leeuwen FE, Hodgson DC. Methods to assess adverse health-related outcomes in cancer survivors. Cancer Epidemiol Biomark Prev. 2011;20(10):2022–34. https://doi.org/10.1158/1055-9965.EPI-11-0674.CrossRef

Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705–15. https://doi.org/10.1001/jama.297.24.2705.CrossRefPubMed

Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–81. https://doi.org/10.1001/jama.2013.6296.CrossRefPubMedPubMedCentral

Armenian SH, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the bone marrow transplant survivor study (BMTSS) and childhood cancer survivor study (CCSS). Blood. 2011;118(5):1413–20. https://doi.org/10.1182/blood-2011-01-331835.CrossRefPubMedPubMedCentral

Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the childhood cancer survivor study. J Natl Cancer Inst. 2009;101(13):946–58. https://doi.org/10.1093/jnci/djp148.CrossRefPubMedPubMedCentral

Essig S, Li Q, Chen Y, Hitzler J, Leisenring W, Greenberg M, et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the childhood cancer survivor study cohort. Lancet Oncol. 2014;15(8):841–51. https://doi.org/10.1016/S1470-2045(14)70265-7.CrossRefPubMedPubMedCentral

Friedman DN, Chou JF, Oeffinger KC, Kleinerman RA, Ford JS, Sklar CA, et al. Chronic medical conditions in adult survivors of retinoblastoma: results of the retinoblastoma survivor study. Cancer. 2016;122(5):773–81. https://doi.org/10.1002/cncr.29704.CrossRefPubMedPubMedCentral

10.

Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst. 2010;102(16):1272–83. https://doi.org/10.1093/jnci/djq278.CrossRefPubMedPubMedCentral

11.

Ishida Y, Honda M, Ozono S, Okamura J, Asami K, Maeda N, et al. Late effects and quality of life of childhood cancer survivors: part 1. Impact of stem cell transplantation. Int J Hematol. 2010;91(5):865–76. https://doi.org/10.1007/s12185-010-0584-y.CrossRefPubMed

12.

King AA, Seidel K, Di C, Leisenring WM, Perkins SM, Krull KR, et al. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the childhood cancer survivor study. Neuro-Oncology. 2017;19(5):689–98. https://doi.org/10.1093/neuonc/now242.CrossRefPubMed

13.

Laverdiere C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, et al. Long-term outcomes in survivors of neuroblastoma: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2009;101(16):1131–40. https://doi.org/10.1093/jnci/djp230.CrossRefPubMedPubMedCentral

14.

Liu Q, Leisenring WM, Ness KK, Robison LL, Armstrong GT, Yasui Y, et al. Racial/ethnic differences in adverse outcomes among childhood cancer survivors: the childhood cancer survivor study. J Clin Oncol. 2016;34(14):1634–43. https://doi.org/10.1200/JCO.2015.66.3567.CrossRefPubMedPubMedCentral

15.

Marina NM, Liu Q, Donaldson SS, Sklar CA, Armstrong GT, Oeffinger KC, et al. Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the childhood Cancer survivor study. Cancer. 2017;123(13):2551–60. https://doi.org/10.1002/cncr.30627.CrossRefPubMedPubMedCentral

16.

Michel G, Greenfield DM, Absolom K, Ross RJ, Davies H, Eiser C. Follow-up care after childhood cancer: survivors’ expectations and preferences for care. Eur J Cancer. 2009;45(9):1616–23. https://doi.org/10.1016/j.ejca.2009.02.026.CrossRefPubMed

17.

Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Blood. 2008;111(12):5515–23. https://doi.org/10.1182/blood-2007-10-117150.CrossRefPubMedPubMedCentral

18.

Mulrooney DA, Dover DC, Li S, Yasui Y, Ness KK, Mertens AC, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the childhood cancer survivor study. Cancer. 2008;112(9):2071–9. https://doi.org/10.1002/cncr.23405.CrossRefPubMed

19.

Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, et al. Twenty years of follow-up of survivors of childhood osteosarcoma. Cancer. 2011;117(3):625–34. https://doi.org/10.1002/cncr.25446.CrossRefPubMed

20.

Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82. https://doi.org/10.1056/NEJMsa060185.CrossRefPubMed

21.

Saha A, Salley CG, Saigal P, Rolnitzky L, Goldberg J, Scott S, et al. Late effects in survivors of childhood CNS tumors treated on head start I and II protocols. Pediatr Blood Cancer. 2014;61(9):1644–52; quiz 53-72. https://doi.org/10.1002/pbc.25064.CrossRefPubMedPubMedCentral

22.

Schultz KAP, Chen L, Chen Z, Kawashima T, Oeffinger KC, Woods WG, et al. Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group. Pediatr Blood Cancer. 2014;61(4):729–36. https://doi.org/10.1002/pbc.24881.CrossRefPubMed

23.

Stevens MC, Mahler H, Parkes S. The health status of adult survivors of cancer in childhood. Eur J Cancer. 1998;34(5):694–8.CrossRef

24.

Termuhlen AM, Tersak JM, Liu Q, Yasui Y, Stovall M, Weathers R, et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2011;57(7):1210–6. https://doi.org/10.1002/pbc.23090.CrossRefPubMedPubMedCentral

25.

Armstrong AE, Danner-Koptik K, Golden S, Schneiderman J, Kletzel M, Reichek J, et al. Late effects in pediatric high-risk Neuroblastoma survivors after intensive induction chemotherapy followed by myeloablative consolidation chemotherapy and triple autologous stem cell transplants. J Pediatr Hematol Oncol. 2018;40(1):31–5. https://doi.org/10.1097/MPH.0000000000000848.CrossRefPubMed

26.

Blaauwbroek R, Groenier KH, Kamps WA, Meyboom-de Jong B, Postma A. Late effects in adult survivors of childhood cancer: the need for life-long follow-up. Ann Oncol. 2007;18(11):1898–902. https://doi.org/10.1093/annonc/mdm336.CrossRefPubMed

27.

Faraci M, Barra S, Cohen A, Lanino E, Grisolia F, Miano M, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys. 2005;63(5):1568–75. https://doi.org/10.1016/j.ijrobp.2005.04.031.CrossRefPubMed

28.

Lannering B, Marky I, Lundberg A, Olsson E. Long-term sequelae after pediatric brain tumors: their effect on disability and quality of life. Med Pediatr Oncol. 1990;18(4):304–10.CrossRef

29.

Oeffinger KC, Eshelman DA, Tomlinson GE, Buchanan GR, Foster BM. Grading of late effects in young adult survivors of childhood cancer followed in an ambulatory adult setting. Cancer. 2000;88(7):1687–95.CrossRef

30.

Parigi GB, Beluffi G, Corbella F, Matteotti C, Ramella B, Bragheri R. Long-term follow-up in children treated for retroperitoneal malignant tumours. Eur J Pediatr Surg. 2003;13(4):240–4. https://doi.org/10.1055/s-2003-42243.CrossRefPubMed

31.

Spunberg JJ, Chang CH, Goldman M, Auricchio E, Bell JJ. Quality of long-term survival following irradiation for intracranial tumors in children under the age of two. Int J Radiat Oncol Biol Phys. 1981;7(6):727–36.CrossRef

32.

Taylor RE. Morbidity from abdominal radiotherapy in the first United Kingdom Children’s Cancer Study Group Wilms’ Tumour study. United Kingdom Children's Cancer Study Group. Clin Oncol (R Coll Radiol). 1997;9(6):381–4.CrossRef

33.

Von der Weid N, Beck D, Caflisch U, Feldges A, Wyss M, Wagner H. Standardized assessment of late effects in long-term survivors of childhood cancer in Switzerland. Int J Pediatr Hematol Oncol. 1996;3(6):483–90.

34.

Von der Weid N. Swiss pediatric oncology group. Late effects in long-term survivors of all in childhood: experiences from the SPOG late effects study. Swiss Med Wkly. 2001;131(13–14):180–7.PubMed

35.

Chao C, Xu L, Bell E, Cooper R, Mueller L. Long-term health outcomes in survivors of childhood cancer diagnosed between 1990 and 2000 in a large US integrated health care system. J Pediatr Hematol Oncol. 2016;38(2):123–30. https://doi.org/10.1097/MPH.0000000000000492.CrossRefPubMed

36.

Gunn ME, Malila N, Lahdesmaki T, Arola M, Gronroos M, Matomaki J, et al. Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based study. Neuro-Oncology. 2015;17(10):1412–8. https://doi.org/10.1093/neuonc/nov115.CrossRefPubMedPubMedCentral

37.

de Fine LS, Rugbjerg K, Gudmundsdottir T, Bonnesen TG, Asdahl PH, Holmqvist AS, et al. Long-term inpatient disease burden in the adult life after childhood cancer in Scandinavia (ALiCCS) study: a cohort study of 21,297 childhood cancer survivors. PLoS Med. 2017;14(5):e1002296. https://doi.org/10.1371/journal.pmed.1002296.CrossRef

38.

Font-Gonzalez A, Feijen E, Geskus RB, Dijkgraaf MGW, van der Pal HJH, Heinen RC, et al. Risk and associated risk factors of hospitalization for specific health problems over time in childhood cancer survivors: a medical record linkage study. Cancer Med. 2017;6(5):1123–34. https://doi.org/10.1002/cam4.1057.CrossRefPubMedPubMedCentral

39.

Sieswerda E, Font-Gonzalez A, Reitsma JB, Dijkgraaf MG, Heinen RC, Jaspers MW, et al. High hospitalization rates in survivors of childhood cancer: a longitudinal follow-up study using medical record linkage. PLoS One. 2016;11(7):e0159518. https://doi.org/10.1371/journal.pone.0159518.CrossRefPubMedPubMedCentral

40.

U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009.

41.

Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude lifetime cohort study (SJLIFE). Lancet. 2017;390(10112):2569–82. https://doi.org/10.1016/S0140-6736(17)31610-0.CrossRefPubMedPubMedCentral

42.

Hudson MM, Ehrhardt MJ, Bhakta N, Baassiri M, Eissa H, Chemaitilly W, et al. Approach for classification and severity grading of long-term and late-onset health events among childhood Cancer survivors in the St. Jude lifetime cohort. Cancer Epidemiol Biomark Prev. 2017;26(5):666–74. https://doi.org/10.1158/1055-9965.EPI-16-0812.CrossRef

43.

Erman N, Todorovski L, Jereb B. Late somatic sequelae after treatment of childhood cancer in Slovenia. BMC Res Notes. 2012;5:254. https://doi.org/10.1186/1756-0500-5-254.CrossRefPubMedPubMedCentral

44.

Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, van der Pal HJ, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J Clin Oncol. 2017;35(20):2288–98. https://doi.org/10.1200/JCO.2016.71.6902.CrossRefPubMed

45.

CCRF Epidemiology Research Unit, Division of Epidemiology/Clinical Research, Department of Pediatrics. Long-term follow-up study of individuals treated for cancer, leukemia, tumor or similar illness. https://ccss.stjude.org/content/dam/en_US/shared/ccss/documents/survey/survey-baseline.pdf. Accessed 7 Feb 2020.

46.

Department of Public Health and Epidemiology, University of Birmingham. Study of people treated for cancer, leukaemia, tumour or similar illness in childhood. https://www.birmingham.ac.uk/Documents/college-mds/haps/projects/cancerPH/bccss/completeqm.pdf. Accessed 7 Feb 2020.

47.

Goldsby RE, Stratton KL, Raber S, Ablin A, Strong LC, Oeffinger K, et al. Long-term sequelae in survivors of childhood leukemia with down syndrome: a childhood cancer survivor study report. Cancer. 2018;124(3):617–25. https://doi.org/10.1002/cncr.31065.CrossRefPubMed

48.

Hudson MM, Oeffinger KC, Jones K, Brinkman TM, Krull KR, Mulrooney DA, et al. Age-dependent changes in health status in the childhood cancer survivor cohort. J Clin Oncol. 2015;33(5):479–91. https://doi.org/10.1200/JCO.2014.57.4863.CrossRefPubMed

49.

Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011;117(3):625–34. https://doi.org/10.1002/cncr.25446.CrossRefPubMed

50.

Wells EM, Ullrich NJ, Seidel K, Leisenring W, Sklar CA, Armstrong GT, et al. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a childhood cancer survivor study report. Neuro-Oncology. 2018;20(1):132–42. https://doi.org/10.1093/neuonc/nox148.CrossRefPubMed

51.

Hawkins MM, Lancashire ER, Winter DL, Frobisher C, Reulen RC, Taylor AJ, et al. The British childhood cancer survivor study: objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer. 2008;50(5):1018–25. https://doi.org/10.1002/pbc.21335.CrossRefPubMed

52.

Wong KF, Reulen RC, Winter DL, Guha J, Fidler MM, Kelly J, et al. Risk of adverse health and social outcomes up to 50 years after Wilms tumor: the British childhood cancer survivor study. J Clin Oncol. 2016;34(15):1772–9. https://doi.org/10.1200/JCO.2015.64.4344.CrossRefPubMed

53.

Kenney LB, Nancarrow CM, Najita J, Vrooman LM, Rothwell M, Recklitis C, et al. Health status of the oldest adult survivors of cancer during childhood. Cancer. 2010;116(2):497–505. https://doi.org/10.1002/cncr.24718.CrossRefPubMed

54.

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9). https://doi.org/10.1093/jnci/dju244.

55.

Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the international late effects of childhood Cancer guideline harmonization group. Pediatr Blood Cancer. 2013;60(4):543–9. https://doi.org/10.1002/pbc.24445.CrossRefPubMed

Title: The Dutch LATER physical outcomes set for self-reported data in survivors of childhood cancer
Authors: Nina Streefkerk
Wim J. E. Tissing
Margriet van der Heiden-van der Loo
Elizabeth A. M. (Lieke) Feijen
Eline van Dulmen-den Broeder
Jacqueline J. Loonen
Helena J. H. van der Pal
Cécile M. Ronckers
Hanneke M. van Santen
Marleen H. van den Berg
Renée L. Mulder
Joke C. Korevaar
Leontine C. M. Kremer
Publication date: 01-10-2020
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 5/2020
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-020-00880-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purposes

Methods

Results

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 5/2020

Healthcare services and medication use among cancer survivors and their partners: a cross-sectional analysis of 16 European countries

Influence of provider recommendations to restart vaccines after childhood cancer on caregiver intention to vaccinate

Beyond broadband: digital inclusion as a driver of inequities in access to rural cancer care

Addressing the needs of cancer survivors during the COVID-19 pandemic

Physical activity and nutrition interventions for older adults with cancer: a systematic review

Relationship of menopausal symptoms and ovarian reserve in reproductive-aged cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer